HighTide Therapeutics Inc
Company Profile
Business description
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Contact
Ganli Second Road
18B-102, Zhonghaixin Innovation Industry City
Jihua Neighborhood
Longgang District, Guangdong
Shenzhen518112
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
70
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,005.90 | 44.20 | 0.56% |
| CAC 40 | 7,329.97 | 5.43 | -0.07% |
| DAX 40 | 21,311.02 | 57.32 | 0.27% |
| Dow JONES (US) | 39,669.39 | 699.57 | -1.73% |
| FTSE 100 | 8,275.60 | 26.48 | 0.32% |
| HKSE | 21,334.26 | 277.28 | 1.32% |
| NASDAQ | 16,307.16 | 516.01 | -3.07% |
| Nikkei 225 | 34,208.55 | 288.15 | 0.85% |
| NZX 50 Index | 12,118.99 | 51.07 | 0.42% |
| S&P 500 | 5,275.70 | 120.93 | -2.24% |
| S&P/ASX 200 | 7,803.10 | 44.20 | 0.57% |
| SSE Composite Index | 3,275.22 | 0.79 | -0.02% |